EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis

Data ReadoutMixedCagriSemasemaglutidetirzepatideNeutral

AI Analysis

Summary

CagriSema weight loss data from the REDEFINE-1 trial was presented at EASD 2026, showing the drug maintained weight loss effects at submaximal doses as the company competes in the obesity treatment market against established therapies like semaglutide and tirzepatide.

Clinical Trial Data

Outcome Details

CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis

Importance:5/10

Sentiment:

0.10

obesityweight lossGLP-1 competitorEASD conferenceclinical data

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 30, 2026 4:40 PM

Read Original